Investing.com - Aslan Pharma ADR reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Aslan Pharma ADR announced earnings per share of $-0.12 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.1233 on revenue of $0.00.
Aslan Pharma ADR shares are down 22.4% from the beginning of the year and are trading at $1.420 , down-from-52-week-high.They are under-performing the Nasdaq which is up 18.48% from the start of the year.
Aslan Pharma ADR shares gained 2.16% in intra-day trade the report.
Aslan Pharma ADR follows other major Healthcare sector earnings this month
Aslan Pharma ADR's report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.
Abbott Labs had beat expectations on October 20 with third quarter EPS of $1.4 on revenue of $10.93B, compared to forecast for EPS of $0.9449 on revenue of $9.56B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar